A Brief History of OspA Vaccines Including Their Impact on Diagnostic Testing for Lyme Disease
Diagnostic Microbiology and Infectious Disease
The only United States Food and Drug Administration approved vaccine preparation to prevent Lyme disease consisted of a single recombinant outer surface protein A (OspA), which was marketed for use from late 1998 until early 2002, with no vaccine currently available for humans for nearly 20 years. OspA vaccines generate an antibody-mediated, transmission blocking immunity, that prevents Borrelia burgdorferi from being transmitted during a tick bite. Although this OspA vaccine was safe and effective, it likely would have required booster doses to maintain immunity, and vaccination regularly caused false positive results on first-tier serologic testing for Lyme disease, when a whole cell-based enzyme immunoassay was used. Clinical trials are in progress to test a new multivalent OspA vaccine designed to prevent Lyme disease in both the United States and Europe.
Wormser, G. P. (2022). A Brief History of OspA Vaccines Including Their Impact on Diagnostic Testing for Lyme Disease. Diagnostic Microbiology and Infectious Disease, 102 (1), 115572. https://doi.org/10.1016/j.diagmicrobio.2021.115572